Menu

Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools

Proteintech, the benchmark in antibodies, today   announces  the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies. 

Proteintech Group
Oct 22, 2020

ChromoTek is the market leader in nanobodies — high-performance recombinant reagents used for breakthrough research discoveries.  The combined companies will better address the industry’s growing opportunities and challenges in single cell analysis, super resolution imaging, and multiplex assays.  

“Our fit-for-purpose nanobody-based tools perfectly complement the comprehensive antibody coverage of the proteome that Proteintech offers,” said Dr. Marion Jung, CEO of ChromoTek.  “It is exciting to be working together with a company that shares our common values in reproducibility and quality for the benefit of research and beyond.”          

Dr. Jason Li, CEO of Proteintech said, “This new partnership will deliver considerable value to the market.  With global manufacturing across three continents, not only will we serve the research market better, but we’ll also deeply impact translational science and therapeutic applications.” 

November 2020

Death on the shore

Researchers investigate recent gray whale strandings along North America’s Pacific coast

Marketplace

Sponsored Product Updates

Twist Bioscience and Biotia Announce Research Use Only Availability of First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay for Characterization and Surveillance of the Virus
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today announced the availability of an important new research tool for the sequencing and surveillance of COVID-19.
The Rise of Cannabis Extraction Labs
Scientists in cannabis extraction laboratories are bravely pioneering a new field of agro-chemical engineering.
Expanding Cell Growth Capabilities
Download this eBook to learn how to optimize large-scale cell growth using culture shakers, incubators, and bioreactors!
SynDevRx Announces Positive Data from Phase 1 Safety Trial of SDX-7320 in Late Stage Cancer Patients
SynDevRx has submitted to the FDA results from a Phase 1 dose escalation study in patients with metastatic and progressing solid tumors to assess the safety and tolerability of SDX-7320. Additional outcome measures suggest that SDX-7320 may slow the rate of disease progression and formation of new metastases. Exploratory endpoints suggest that SDX-7320 may induce favorable changes to insulin and insulin resistance and other key metabolic hormones (leptin, adiponectin) as well as to multiple angiogenic biomarkers.